RecruitingPhase 1 / Phase 2NCT06362252
A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)
Sponsor: Daiichi Sankyo
Lancaster, PA · Philadelphia, PA · +23 more sites